Technical Analysis for CASI - CASI Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 3.21 0.63% 0.02
CASI closed up 0.63 percent on Friday, December 6, 2019, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Flat Down Down
See historical CASI trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Spinning Top Other 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish 0.63%
Oversold Stochastic Weakness 0.63%

Older signals for CASI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company's lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Biotechnology Cancer Life Sciences Pharmaceutical Diseases Treatment Of Cancer Autoimmune Diseases Multiple Myeloma Cancer Treatment Leukemia Pyrrolidines Cyclacel Advanced Solid Tumors Pacritinib

Is CASI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.58
52 Week Low 2.83
Average Volume 104,387
200-Day Moving Average 3.22
50-Day Moving Average 3.27
20-Day Moving Average 3.29
10-Day Moving Average 3.31
Average True Range 0.13
ADX 15.52
+DI 20.97
-DI 19.59
Chandelier Exit (Long, 3 ATRs ) 3.19
Chandelier Exit (Short, 3 ATRs ) 3.49
Upper Bollinger Band 3.48
Lower Bollinger Band 3.09
Percent B (%b) 0.3
BandWidth 11.82
MACD Line -0.02
MACD Signal Line 0.00
MACD Histogram -0.018
Fundamentals Value
Market Cap 193.24 Million
Num Shares 60.2 Million
EPS -0.13
Price-to-Earnings (P/E) Ratio -24.69
Price-to-Sales 0.00
Price-to-Book 7.28
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.29
Resistance 3 (R3) 3.28 3.26 3.27
Resistance 2 (R2) 3.26 3.24 3.26 3.27
Resistance 1 (R1) 3.23 3.23 3.25 3.24 3.26
Pivot Point 3.21 3.21 3.21 3.21 3.21
Support 1 (S1) 3.18 3.19 3.20 3.19 3.16
Support 2 (S2) 3.16 3.18 3.16 3.15
Support 3 (S3) 3.13 3.16 3.15
Support 4 (S4) 3.14